A Phase 3, Multicenter, Randomized, Open-Label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-Resistant/Refractory Ovarian Cancer

Trial ID # NCT02580058; JAVELIN Ovarian 200
Phase III
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-L1
Drug Name Avelumab
Alternate Drug Names Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio
Drugs in Trial Avelumab, Liposomal doxorubicin
Eligible Participant

Platinum resistant or refractory ovarian cancer with < 4 prior therapies

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Randomized


ORR, PFS, OS, evaluated per RECIST


Ave+PLD vs Ave vs PLD:

ORR: 13.3 vs 3.7 vs 4.2%
PFS: 3.7 vs 1.9 vs 3.5 months, HR: 0.78 (0.59-1.24, p=0.03); HR: 1.68 (1.32-2.60, p>0.99)
OS: 15.7 vs 11.8 vs 13.1 months, HR: 0.89 (0.74-1.24, p=0.21); HR: 1.14 (0.95-1.59, p=0.03)

Exploratory analysis, PD-L1 levels:
PD-L1+ vs PD-L1-: ORR: 19.5 vs 3.4%

Clinically Significant Adverse Events

Ave+PLD vs Ave vs PLD:
Serious AE: 18 vs 7 vs 11%
Grade 3-4 AE: PPE/Hand-Foot Syndrome (10 vs 0 vs 9%)


No significant improvement in ORR, PFS or OS with avelumab+liposomal doxorubicin compared to avelumab or PLD alone


Pujade-Lauraine E et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol (2021) 22(7):1034-1046

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.